Literature DB >> 21496978

Platelets at work in primary hemostasis.

Katleen Broos1, Hendrik B Feys, Simon F De Meyer, Karen Vanhoorelbeke, Hans Deckmyn.   

Abstract

When platelet numbers are low or when their function is disabled, the risk of bleeding is high, which on the one hand indicates that in normal life vascular damage is a rather common event and that hence the role of platelets in maintaining a normal hemostasis is a continuously ongoing physiological process. Upon vascular injury, platelets instantly adhere to the exposed extracellular matrix resulting in platelet activation and aggregation to form a hemostatic plug. This self-amplifying mechanism nevertheless requires a tight control to prevent uncontrolled platelet aggregate formation that eventually would occlude the vessel. Therefore endothelial cells produce inhibitory compounds such as prostacyclin and nitric oxide that limit the growth of the platelet thrombus to the damaged area. With this review, we intend to give an integrated survey of the platelet response to vascular injury in normal hemostasis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21496978     DOI: 10.1016/j.blre.2011.03.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  94 in total

1.  JAM-A protects from thrombosis by suppressing integrin αIIbβ3-dependent outside-in signaling in platelets.

Authors:  Meghna U Naik; Timothy J Stalker; Lawrence F Brass; Ulhas P Naik
Journal:  Blood       Date:  2012-01-23       Impact factor: 22.113

2.  CLEC-2 expression is maintained on activated platelets and on platelet microparticles.

Authors:  Eelo Gitz; Alice Y Pollitt; Jerney J Gitz-Francois; Osama Alshehri; Jun Mori; Samantha Montague; Gerard B Nash; Michael R Douglas; Elizabeth E Gardiner; Robert K Andrews; Christopher D Buckley; Paul Harrison; Steve P Watson
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

3.  Lin28b regulates age-dependent differences in murine platelet function.

Authors:  Massiel Chavez Stolla; Seana C Catherman; Paul D Kingsley; R Grant Rowe; Anne D Koniski; Katherine Fegan; Leah Vit; Kathleen E McGrath; George Q Daley; James Palis
Journal:  Blood Adv       Date:  2019-01-08

4.  Antiplatelet therapy as a modulator of stroke aetiology: a meta-analysis.

Authors:  Christopher A Rajkumar; Christopher N Floyd; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

5.  Platelet microRNAs and vascular injury.

Authors:  Elena V Dolmatova; Kathy K Griendling
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

6.  Platelet-derived miR-223 promotes a phenotypic switch in arterial injury repair.

Authors:  Zhi Zeng; Luoxing Xia; Xuejiao Fan; Allison C Ostriker; Timur Yarovinsky; Meiling Su; Yuan Zhang; Xiangwen Peng; Yi Xie; Lei Pi; Xiaoqiong Gu; Sookja Kim Chung; Kathleen A Martin; Renjing Liu; John Hwa; Wai Ho Tang
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

Review 7.  Novel therapy for liver regeneration by increasing the number of platelets.

Authors:  Kazuhiro Takahashi; Soichiro Murata; Nobuhiro Ohkohchi
Journal:  Surg Today       Date:  2012-11-21       Impact factor: 2.549

8.  Hemocompatibility assessment of two siRNA nanocarrier formulations.

Authors:  Afrouz Yousefi; Marianne Lauwers; Reka Nemes; Thijs van Holten; Negar Babae; Mark Roest; Gert Storm; Raymond Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

9.  Mice Expressing Low Levels of CalDAG-GEFI Exhibit Markedly Impaired Platelet Activation With Minor Impact on Hemostasis.

Authors:  Raymond Piatt; David S Paul; Robert H Lee; Steven E McKenzie; Leslie V Parise; Dale O Cowley; Brian C Cooley; Wolfgang Bergmeier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-14       Impact factor: 8.311

10.  Review of quantitative systems pharmacological modeling in thrombosis.

Authors:  Limei Cheng; Guo-Wei Wei; Tarek Leil
Journal:  Commun Inf Syst       Date:  2019-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.